Analysts Offer Insights on Healthcare Companies: Melinta Therapeutics Inc (MLNT), Stemline Therapeutics Inc (STML) and Karyopharm Therapeutics (KPTI)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Melinta Therapeutics Inc (MLNT), Stemline Therapeutics Inc (STML) and Karyopharm Therapeutics (KPTI) with bullish sentiments.

Melinta Therapeutics Inc (MLNT)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Melinta Therapeutics Inc, with a price target of $13. The company’s shares closed yesterday at $6.41, close to its 52-week low of $1.62.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.8% and a 37.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Melinta Therapeutics Inc with a $24.67 average price target, which is a 284.9% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price target.

See today’s analyst top recommended stocks >>

Stemline Therapeutics Inc (STML)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc, with a price target of $35. The company’s shares closed yesterday at $15.63.

Selvaraju noted:

“We reiterate our Buy rating and $35 price target. Expecting EU approval in BPDCN in 2H19. Agency (EMA) completed its validation of the Marketing Authorization Application (MAA) for ELZONRIS to treat BPDCN.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 3.1% and a 33.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $28.67, an 83.4% upside from current levels. In a report released today, J.P. Morgan also reiterated a Buy rating on the stock.

Karyopharm Therapeutics (KPTI)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics, with a price target of $29. The company’s shares closed yesterday at $5.94, close to its 52-week low of $3.92.

According to TipRanks.com, White is a 5-star analyst with an average return of 17.8% and a 50.7% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.

Karyopharm Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $29.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts